المؤلفون: Spiliotis, John, Iavazzo, Christos, Fotiou, Alexandros, Kopanakis, Nikolaos, Terra, Alexios, Efstathiou, Elias, Margari, Charalambia, Tsiatas, Marinos

المصدر: J Surg Oncol ; ISSN:1096-9098 ; Volume:123 ; Issue:2

مصطلحات موضوعية: HIPEC, intermediate, ovarian cancer, survival, upfront

الوصف: Newly diagnosed advanced-stage ovarian cancer patients are treated with neoadjuvant chemotherapy, primary or intermediate cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study is to evaluate the optimal timing of cytoreduction plus HIPEC for advanced ovarian cancer patients.

العلاقة: https://doi.org/10.1002/jso.26280Test; https://pubmed.ncbi.nlm.nih.gov/33125733Test

الإتاحة: https://doi.org/10.1002/jso.26280Test
https://pubmed.ncbi.nlm.nih.gov/33125733Test

المؤلفون: Biacchi, Daniele, Accarpio, Fabio, Ansaloni, Luca, Macrì, Antonio, Ciardi, Antonio, Federici, Orietta, Spagnoli, Alessandra, Cavaliere, Davide, Vaira, Marco, Sapienza, Paolo, Sammartino, Paolo

المصدر: J Surg Oncol ; ISSN:1096-9098 ; Volume:120 ; Issue:7

مصطلحات موضوعية: HIPEC, interval debulking surgery, neoadjuvant chemotherapy, ovarian high-grade serous carcinoma, upfront debulking surgery

الوصف: Whether patients with advanced tubo-ovarian high-grade serous cancer (HGSC) fare better after upfront debulking surgery (UDS) or neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS) remains controversial.

العلاقة: https://doi.org/10.1002/jso.25703Test; https://pubmed.ncbi.nlm.nih.gov/31531879Test

الإتاحة: https://doi.org/10.1002/jso.25703Test
https://pubmed.ncbi.nlm.nih.gov/31531879Test